Case report: A case of complete clinical response in a patient experiencing high microsatellite instability unresectable colon cancer being treated with a PD-L1 inhibitor after interstitial pneumonia

Frontiers in Oncology

Oncology

Haibo Mou¹  Xuehua Hou¹  Luo Wang¹  Qin Liao¹ 

[1] Department of Medical Oncology, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University, Shulan International Medical College, Hangzhou, China;

关键词: case report;    colon cancer;    PD-L1 inhibitor;    MSI-H;    interstitial lung disease;   

DOI  :  10.3389/fonc.2023.1126769

 received in 2022-12-18, accepted in 2023-02-27,  发布年份 2023

来源: Frontiers

【 摘 要 】

Immune checkpoint inhibitors (ICI) have dramatically transformed the treatment landscape for metastatic colorectal cancer (mCRC) with deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H). Envafolimab, a novel programmed death-1 ligand 1 (PD-L1) inhibitor, has been reported to be efficient and safe for the management of advanced MSI-H/dMMR solid tumors. Here, we report the case of a 35-year-old female patient with MSI-H/dMMR mCRC who was treated with envafolimab following mFOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) plus bevacizumab. While suffering from interstitial pneumonia after chemotherapy, the patient achieved a complete clinical response with the use of envafolimab without additional adverse events. Thus, PD-L1 inhibitors may be potential candidates for treating patients with MSI-H/dMMR mCRC.

【 授权许可】

Unknown   
Copyright © 2023 Wang, Mou, Hou and Liao